title: Vismodegib resistance in basal cell carcinoma: not a smooth fit.
abstract: In this issue of Cancer Cell, two complementary papers by Atwood and colleagues and Sharpe and colleagues show that basal cell carcinomas resistant to the Smoothened (SMO) inhibitor vismodegib frequently harbor SMO mutations that limit drug binding, with mutations at some sites also increasing basal SMO activity.
authors.affiliation: Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, BRB 1053, 421 Curie Boulevard, Philadelphia, PA 19104, USA.
authors.forename: Todd W
authors.initials: TW
authors.lastname: Ridky
authors.affiliation: Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, BRB 1053, 421 Curie Boulevard, Philadelphia, PA 19104, USA. Electronic address: cotsarel@mail.med.upenn.edu.
authors.forename: George
authors.initials: G
authors.lastname: Cotsarelis
mesh_terms: D000813:Anilides / Q000627:therapeutic use*; D002280:Basal Cell Carcinoma / Q000188:drug therapy* / Q000235:genetics*; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D006801:Humans; D011725:Pyridines / Q000627:therapeutic use*; D043562:Receptors, G-Protein-Coupled / Q000235:genetics*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D000072086:Smoothened Receptor
chemical_list: D000813:Anilides; C538724:HhAntag691; D011725:Pyridines; D043562:Receptors, G-Protein-Coupled; C491023:SMO protein, human; D000072086:Smoothened Receptor